Bio-rad Laboratories, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
SCHEDULE 13G/A: BlackRock Boosts Bio-Rad Class A Stock Stake to 7.4%
BlackRock, Inc. has reported an aggregate beneficial ownership of 7.4% of Bio-Rad Laboratories, Inc.'s Class A Stock, totaling 1,618,123 shares.
NYSE
First Eagle Investment Management and its Global Fund have reported an 11.4% beneficial ownership stake in Bio-Rad Laboratories Inc.
NYSE
First Eagle Investment Management, LLC and its affiliate, First Eagle Global Fund, have disclosed a significant beneficial ownership stake of 10.0% in Bio-Rad Laboratories Inc.'s common stock.
NYSE
First Eagle Investment Management, LLC has reported a significant beneficial ownership stake of 6.8% in Bio-Rad Laboratories Inc., as detailed in a recent Schedule 13G filing with the SEC.
NYSE
Bio-Rad Laboratories, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 9.66% of Oncocyte Corporation's common shares as of February 10, 2025.